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Bicuspid aortic valve outcomes
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Abstract Background: Bicuspid aortic valve is the most common CHD. Its association with early valvular
dysfunction, endocarditis, thoracic aorta dilatation, and aortic dissection is well established. Objective: The aim
of this study was to assess the incidence and predictors of cardiac events in adults with bicuspid aortic valve.
Methods: We carried out a retrospective analysis of cardiac outcomes in ambulatory adults with bicuspid aortic
valve followed-up in a tertiary hospital centre. Outcomes were deﬁned as follows: interventional – intervention on
the aortic valve or thoracic aorta; medical – death, aortic dissection, aortic valve endocarditis, congestive heart
failure, arrhythmias, or ischaemic heart disease requiring hospital admission; and a composite end point of both.
Kaplan–Meier curves were generated to determine event rates, and predictors of cardiac events were determined
by multivariate analysis. Results: A total of 227 patients were followed-up over 13± 9 years; 29% of patients
developed severe aortic valve dysfunction and 12.3% reached ascending thoracic aorta dimensions above 45mm.
At least one cardiac outcome occurred in 38.8% of patients, with an incidence rate at 20 years of follow-up of
47± 4%; 33% of patients were submitted to an aortic valve or thoracic aorta intervention. Survival 20 years after
diagnosis was 94± 2%. Independent predictors of the composite end point were baseline moderate–severe aortic
valve dysfunction (hazard ratio, 3.19; 95% conﬁdence interval, 1.35–7.54; p< 0.01) and aortic valve leaﬂets
calciﬁcation (hazard ratio, 4.72; 95% conﬁdence interval, 1.91–11.64; p< 0.005). Conclusions: In this study of
bicuspid aortic valve, the long-term survival was excellent but with occurrence of frequent cardiovascular events.
Baseline aortic valve calciﬁcation and dysfunction were the only independent predictors of events.
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BICUSPID AORTIC VALVE IS THE MOST COMMON CHD,
1–3
affecting 1.3% of the population.1 Despite
advances in our knowledge, since its ﬁrst
descriptions, for ﬁve centuries,4 there are still
knowledge gaps and areas where further research is
warranted. The heterogeneous clinical presentation
and course, morbid consequences of early valvular
dysfunction requiring surgery, and the possibility of
life-threatening complications justiﬁes continued
efforts to understand this CHD.
The purposes of this retrospective study were to
examine disease progression and cardiac outcomes in a
group of adults with bicuspid aortic valve followed-up
over a prolonged period of observation and to deter-
mine predictors of adverse cardiac outcomes.
Material and methods
Study subjects
This retrospective study examined a referral population
of consecutive adults with bicuspid aortic valve assessed
at the ambulatory adult CHD clinic of the Santa Marta
Hospital from 1990 through 2015. Patients were
identiﬁed using the hospital CHD database. The
inclusion criterion was bicuspid aortic valve docu-
mented on transthoracic echocardiography. Patients for
whom we had no access to baseline echocardiography
and those submitted to aortic valve replacement or
ascending aortic graft surgery previously were excluded.
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Assessments
Baseline data were obtained from the record of the
patient’s ﬁrst visit to the ambulatory clinic. Baseline
data included age, sex, reason for referral, coronary
risk factors, cardiac medications, associated cardiac
diseases, previous cardiac procedures, and echo-
cardiographic parameters. Follow-up data up to
September, 2015 were obtained by review of clinical
records, which included summaries of ambulatory
visits, procedures, and hospital admissions.
Doppler and two-dimensional transthoracic echo-
cardiography examinations performed at baseline and
during the follow-up period at the discretion of the
attending physician were reviewed by one of the
researchers’ echocardiographer in order to standardise
the variables evaluated and to ensure uniformity of
results. Bicuspid aortic valve was diagnosed when
only two cusps were identiﬁed in the short-axis
parasternal view. The type of bicuspid aortic valve
was classiﬁed into type 1, from right–left coronary
cusp fusion, type 2, from right-non coronary cusp
fusion, and type 3, from left-non coronary cusp
fusion,5 in patients who had not undergone previous
intervention on the aortic valve and in whom leaﬂet
orientation could be clearly visualised. Valve degen-
eration was evaluated according to the presence of
thickening and calciﬁcation. Aortic stenosis was
classiﬁed as mild (valve area >1.5 cm2, mean Doppler
gradient <25mmHg, maximum jet velocity
2.0–3.0m/s), moderate (valve area 1–1.5 cm2, mean
Doppler gradient 25–40mmHg, maximum jet
velocity 3.0–4.0m/s), or severe (valve area <1 cm2,
mean Doppler gradient >40mmHg, maximum jet
velocity >4.0m/s).6 In all patients diagnosed before
continuous-wave Doppler became available, wide
valvular opening ascertained the absence of valve
stenosis. Aortic regurgitation was classiﬁed as mild,
moderate, or severe using an integrated approach
taking into consideration the following color and
continuous ﬂow Doppler criteria: ratio of the regur-
gitant jet width to the left ventricular outﬂow tract
width, ratio of the regurgitant jet area to the left
ventricular outﬂow tract area, pressure half-time,
effective regurgitant oriﬁce area, regurgitant volume,
and presence of holodiastolic retrograde ﬂow in the
descending aorta.6,7 Other transthoracic echocardio-
graphy parameters recorded were left parasternal
long-axis M-mode left ventricular end-diastolic dia-
meter, left ventricular end-systolic diameter, end-
diastolic posterior wall thickness, end-diastolic
interventricular septum thickness, left atrium size,
right ventricle size, end-diastolic measurements of
the aortic sinus at the sinus of Valsalva level, and
proximal ascending aortic dimensions. The presence
or absence of left atrial enlargement, left ventricular
dilatation, left ventricular hypertrophy, and right
ventricular dilatation was also assessed according to
criteria deﬁned by Otto et al.8 Dilated aortic sinus and
proximal ascending aorta were deﬁned by dimensions
greater than 40mm irrespective of body surface area.9
The spectrum of aortic dilatation phenotypes was
classiﬁed into type 1, characterised by dilated aortic
root, type 2, enlargement involving the tubular por-
tion of the ascending aorta, and type 3, dilatation of
the entire ascending aorta with sinotubular junction
effacement.10 Left ventricular ejection fraction was
also assessed with visual estimation11 and two-
dimensional echocardiography guidance.12
Outcome measures
The frequency of progression to thoracic aorta dila-
tation and to moderate or severe aortic stenosis or
regurgitation was determined. Aortic growth rate
was deﬁned as the difference between the diameter at
the ﬁrst and the last follow-up echocardiogram –
except in patients undergoing ascending aortic graft
surgery, in which we took into account the last
echocardiogram performed before surgery – divided
by the time interval in years for each patient. It was
considered that a rapid aortic dilatation was present
when the growth rate was above average for the aortic
root or the proximal ascending aorta.
Cardiac outcomes were deﬁned as follows: inter-
ventional, surgery/percutaneous intervention on the
aortic valve or thoracic aorta; medical, death, aortic
dissection, aortic valve endocarditis, congestive heart
failure, arrhythmias, or ischaemic heart disease
requiring hospital admission; and a composite end
point of both, total events, during the follow-up
period. Mortality was determined, and causes of
death were classiﬁed as cardiac, non-cardiac, and
unknown on the basis of review of clinical records
and/or death certiﬁcates.
Statistical analysis
Data analysis was performed using SPSS version 20.
Continuous data are expressed as mean± one standard
deviation, and compared using the unpaired Student
t-test or Wilcoxon’s rank test. Categorical data are dis-
played as frequencies and percentages, and compared
using χ2 tests or Fisher’s exact tests wherever appro-
priate. The two-sided level of signiﬁcance was 0.05.
Kaplan–Meier curves were generated to determine
event rates. Potential predictors of cardiac outcome
were evaluated by univariate Cox regression analyses.
Candidate variables with a p value of <0.05 on
univariate analysis were entered into multivariate Cox
regression models. A stepwise, backward-elimination
algorithm was used. Multivariate logistic regression
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models were also developed to predict a rapid growth
at the ascending and root level separately.
Results
Baseline characteristics
We identiﬁed 287 ambulatory patients with bicuspid
aortic valve followed-up in the adult CHD clinic of
our institution over the past two decades. After
application of exclusion criteria, 227 patients were
included in the analyses. Baseline characteristics are
presented in Table 1. Reasons for referral were aortic
valve dysfunction in 72 patients (31.7%), thoracic
aorta disease including eight cases of thoracic aorta
aneurysm, 3.5%, and nine of aortic coarctation,
4.0%, transition of care from paediatric cardiology to
adult cardiology (116 patients, 51.1%), and other
reasons in the remaining 22, including ﬁve ischaemic
heart disease, four arrhythmia, two hypertension, four
heart failure, three endocarditis, two atrial septal
defect, one family history of bicuspid aortic valve, and
one pulmonary stenosis.
Age at ﬁrst medical appointment was 28±14 years
(median, 21 years; range 15–72; interquartile range
19.5). Patients were predominantly male (70.5%); 27%
of patients had hypertension, and 93.5% of them were
receiving antihypertensive drugs. Cardiovascular medi-
cations included β-adrenergic antagonists (11.9%),
calcium channel antagonists (3.2%), angiotensin-
converting enzyme inhibitor/angiotensin II receptor
antagonist (22.8%), diuretics (6.8%), statins (12.8%),
and antiplatelet agents (5.9%).
In all, 67 patients (29.5%) had at least a previous
diagnosis of other associated CHD – 18.9% had
aortic coarctation, 7.5% ventricular septal defect,
1.8% atrial septal defect, 2.2% patent ductus arter-
iosus, and 3.5% others valvulopathies excluding
aortic valve disease, such as pulmonary stenosis,
mitral valve prolapse, or dysplasia. The majority of
Table 1. Baseline characteristics of study participants.
Age (n= 227)* Baseline echocardiogram (n= 227)*
Mean± SD (years) 28± 14 LVEDD (mean± SD) (mm) 52± 7
Age >30 years [n (%)] 72 (59.1) LVESD (mean± SD) (mm) 32± 6
Age >50 years [n (%)] 24 (10.6) LVD [n (%)] 39 (17.2)
Male sex [n (%)] 101 (70.5) LVEF ⩾ 50% [n (%)] 221 (97.4)
Cardiovascular risk factors (n= 219) IVSTh (mean± SD) (mm) 10± 2
Hypertension [n (%)] 60 (27.4) PWTh (mean± SD) (mm) 10± 2
Hyperlipidaemia [n (%)] 31 (14.2) LVH [n (%)] 37 (16.2%)
Diabetes [n (%)] 5 (2.3) LA size (mean± SD) (mm) 34± 6
Smoking status [n (%)] 34 (15.5) LAE [n (%)] 20 (8.8)
Obesity (BMI⩾ 30)** [n (%)] 18 (8.2) RV size (mean± SD) (mm) 20± 5
Cardiovascular medications (n= 219) RVD [n (%)] 4 (1.8)
Β-adrenergic antagonists [n (%)] 26 (11.9) Type of bicuspid aortic valve (n= 83)
Calcium channel antagonists [n (%)] 7 (3.2) 1/2/3 [n (%)] 53/26/4
ACE inhibitors/ARBs [n (%)] 50 (22.8) (63.9/31.3/4.8)
Diuretics [n (%)] 15 (6.8) Aortic valve degeneration
Statins [n (%)] 28 (12.8) Leaﬂet thickening [n (%)] 115 (53.0%)
Oral antidiabetic agents [n (%)] 5 (2.3) Leaﬂet calciﬁcation [n (%)] 36 (16.6%)
Antiplatelet agents [n (%)] 16 (5.9) Peak aortic velocity (mean± SD) (m/s) 2.2± 1.0
Oral anticoagulation [n (%)] 7 (3.2) Peak AV gradient (mean± SD) (mmHg) 24± 24
Syndromes AS severity, mild/moderate/severe [n (%)] 46/22/19
Turner [n (%)] 4 (1.8) (20.3/9.7/8.4)
Marfan [n (%)] 1 (0.4) AR severity, mild/moderate/severe [n (%)] 90/37/6
Associated CHD (39.6/16.3/2.6)
CoA [n (%)] 43 (18.9) AV dysfunction, moderate or severe [n (%)] 74 (32.6)
VSD [n (%)] 17 (7.5) Aortic sinus dimension (mean± SD) (mm) 31± 6
ASD [n (%)] 4 (1.8) TAA dimension (mean± SD) (mm) 35± 11
Others [n (%)] 13 (5.7) Aortic dilatation (>40mm) [n (%)] 32 (14.1)
Previous aortic valve/thoracic aorta interventions Type of aortic dilatation (n= 32)
Aortic valvuloplasty or valvotomy [n (%)] 10 (4.4) 1/2/3 [n (%)] 4/13/15
CoA treatment [n (%)] (n= 43) 33 (76.7) (12.5/40.6/46.9)
ACE= angiotensin-converting enzyme; ARB= angiotensin II receptor blockers; AR= aortic valve regurgitation; AS= aortic valve stenosis; ASD= atrial
septal defect; AV= aortic valve; BMI= body mass index; CoA= aortic coarctation; IVSTh= interventricular septum thickness; LA= left atrium;
LAE= left atrial enlargement; LVD= left ventricular dilatation; LVEDD= left ventricular end-diastolic diameter; LVEF= left ventricular ejection
fraction; LVESD= left ventricular end-systolic diameter; LVH= left ventricular hypertrophy; PWTh= posterior wall thickness; RV= right ventricle;
RVD= right ventricular dilatation; TAA= tubular ascending aorta; VSD= ventricular septal defect
*Unless otherwise indicated
**Calculated as weight in kilograms divided by height in metres squared
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these associated diseases had successful percutaneous/
surgical treatment in childhood, including 77% of
the aortic coarctation cases, or had no haemodynamic
signiﬁcance. A total of 10 patients (4.4%) had
previous aortic valvuloplasty or valvulotomy in
childhood, with two of them having residual
moderate aortic stenosis and regurgitation at their
baseline echocardiogram.
Overall, 74 patients (32.6%) in the study group had
signiﬁcant aortic valve dysfunction –moderate or severe
aortic stenosis or regurgitation – at baseline. Table 2
compares baseline characteristics of these patients with
those without baseline aortic valve dysfunction.
At baseline, the mean diameter of the sinus of
Valsalva and the proximal ascending aorta was 31± 6
and 35± 11mm, respectively. In all, 32 patients
Table 2. Baseline characteristics of patients with and without baseline moderate–severe aortic valve dysfunction.
Baseline AV dysfunction No baseline AV dysfunction P
(n= 74)* (n= 153)*
Age (mean± SD) (years) 35± 16 25± 12 < 0.001
Age >30 years [n (%)] 39 (52.7) 33 (21.6) <0.001
Male sex [n (%)] 57 (77) 103 (67.3) 0.133
Cardiovascular risk factors (n= 70) (n= 149)
Hypertension [n (%)] 24 (34.3) 36 (24.2) 0.117
Hyperlipidaemia [n (%)] 14 (20) 17 (11.4) 0.089
Diabetes [n (%)] 4 (5.7) 1 (0.7) <0.05
Smoking status [n (%)] 13 (18.6) 21 (14.1) 0.394
Obesity (BMI⩾ 30)** [n (%)] 6 (10.2) 8 (6.9) 0.451
Associated CHD
CoA [n (%)] 4 (5.4) 39 (25.5) <0.001
VSD [n (%)] 3 (4.1) 14 (9.2) 0.281
Others [n (%)] 8 (10.8) 11 (7.2) 0.356
Previous aortic valve/thoracic aorta interventions
Aortic valvuloplasty or valvotomy [n (%)] 2 (2.7) 8 (5.2) 0.505
CoA treatment [n (%)] (n= 4) (n= 39)
1 (25) 32 (82.1) <0.05
Baseline echocardiogram
LVEDD (mean± SD) (mm) 56± 9 51± 6 <0.001
LVESD (mean± SD) (mm) 34± 7 30± 5 <0.001
LVD [n (%)] 25 (33.8) 13 (8.5) <0.001
LVEF⩾ 50% [n (%)] 71 (95.9) 150 (98) 0.394
IVSTh (mean± SD) (mm) 11± 3 9± 2 <0.001
PWTh (mean± SD) (mm) 10± 2 9± 2 <0.001
LVH [n (%)] 23 (31.1) 13 (8.5) <0.001
LA size (mean± SD) (mm) 36± 5 33± 5 <0.001
LAE [n (%)] 10 (13.5) 10 (6.5) 0.082
RV size (mean± SD) (mm) 23± 5 19± 5 0.090
RVD [n (%)] 1 (1.4) 2 (1.3) 1.000
Type of BAV (n= 25) (n= 58)
1/2/3 [n (%)] 15/9/1 38/17/3 0.826
(60/36/4) (65.5/29.3/5.2)
AV degeneration
Leaﬂet thickening [n (%)] 60 (81.1) 61 (39.9) <0.001
Leaﬂet calciﬁcation [n (%)] 26 (35.1) 11 (7.2) <0.001
Peak aortic velocity (mean± SD) (m/s) 300± 125 178± 54 <0.001
Peak AV gradient (mean± SD) (mmHg) 15± 10 43± 33 <0.001
Aortic sinus dimension (mean± SD) (mm) 34± 6 30± 6 <0.001
TAA dimension (mean± SD) mm) 42± 12 35± 9 <0.05
Aortic dilatation (>40mm) [n (%)] 15 (20.3) 17 (11.1) 0.063
Type of aortic dilatation (n= 15) (n= 17)
1/2/3 [n (%)] 2/6/7 2/7/8 0.334
(13.3/40/46.7) (11.8/41.2/47.1)
AV= aortic valve; BAV= bicuspid aortic valve; BMI= body mass index; CoA= aortic coarctation; IVSTh= interventricular
septum thickness; LA= left atrium; LAE= left atrial enlargement; LVD= left ventricular dilatation; LVEDD= left ventricular
end-diastolic diameter; LVEF= left ventricular ejection fraction; LVESD= left ventricular end-systolic diameter; LVH= left
ventricular hypertrophy; PWTh= posterior wall thickness; RV= right ventricle; RVD= right ventricular dilatation; TAA=
tubular ascending aorta; VSD= ventricular septal defect
*Unless otherwise indicated
**Calculated as weight in kilograms divided by height in metres squared
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(14.2%) had dilated thoracic aorta – that is, aortic
sinus and/or proximal ascending aortic dimensions
greater than 40mm. The most frequent aortic phe-
notype was dilatation of the entire ascending aorta
(46.9% of cases), followed closely by the isolated
dilatation of tubular ascending aorta (40.6%).
Progression of disease
The 227 patients were followed-up for a mean of
13± 9 years (median, 11 years; range, 0.2–40.7
years; interquartile range 13.3). The frequency and
age at which moderate or severe aortic valve dys-
function and aortic dilatation occurred are listed in
Table 3. Overall, 66 patients (29.1%) developed
severe aortic valve dysfunction during the follow-up
period. The mean age of diagnosis was 43± 13 years.
Root or tubular ascending aorta diameters of >40
and >45mm were observed in 30.8 and 12.3% of
patients, respectively. The mean sinus of Valsalva
dimension and proximal ascending aorta dimension
was 34± 10 and 39± 9mm at the end of an aorta
mean echocardiographic follow-up of 9± 3 years,
respectively. Dilatation progressed at faster rates in
the proximal ascending aorta: the mean rate of change
in aortic sinus dimension was 0.3± 0.6mm/year
(95% conﬁdence interval 0.2–0.4), and the mean
increase in ascending aorta dimension was
0.5± 0.7mm/year (95% conﬁdence interval 0.3–0.7).
In multivariate analysis, the presence of moderate
or severe aortic regurgitation and arterial hypertension
was strongly associated with rapid aortic dilatation
(Table 4).
Primary outcomes
The frequency and nature of outcome events are listed
in Table 5. A total of seven deaths occurred (3.1%), of
which two were cardiac related, two were not related
to a cardiac aetiology, including one case of malig-
nancy and one septic shock, and three were of
unknown reasons. Survival was 96± 2 and 94± 2%
at 10 and 20 years, respectively (Fig 1).
The composite end point – medical or interven-
tional events – occurred in 88 patients (38.8%), with
an incidence rate at 20 years of 47± 4% (Fig 2); 11
patients (4.8%) were diagnosed with bacterial
endocarditis. Aortic dissection and stroke occurred in
two (0.9%) and six patients (2.6%), respectively;
moreover, seven patients (7.5%) required hospital
admission for congestive heart failure (Table 5). The
incidence of cardiovascular medical events was
20± 4% at 20 years of follow-up (Fig 2).
During the follow-up period, aortic valve or
thoracic aorta interventions were performed in 74
patients (32.6%), with an incidence rate at 20 years of
39±4% (Fig 3); 61 patients (26.9%) were subjected
to at least one aortic valve intervention, at a mean age
Table 4. Predictors of rapidly progressive aortic dilatation.
Univariate analysis Multivariate analysis
Candidate variables OR (95% CI) p value OR (95% CI) p value
Baseline age >30 years 1.37 (0.63–2.99) 0.433
Male sex 1.16 (0.56–2.44) 0.690
Hypertension 2.26 (1.00–5.07) 0.049 3.67 (1.31–10.29) 0.014
Hyperlipidaemia 2.60 (0.85–7.94) 0.093
Smoking status 1.80 (0.65–4.96) 0.256
Obesity 1.88 (0.50–7.10) 0.355
Previous diagnosis of CoA 1.80 (0.65–4.96) 0.256
Previous aorta/AV intervention 1.89 (0.85–4.19) 0.116
Baseline aortic dilatation (>40mm) 1.07 (0.38–3.02) 0.903
Moderate–severe AV dysfunction 1.73 (0.82–3.63) 0.148
Moderate–severe AS 1.38 (0.51–3.73) 0.527
Moderate–severe AR 2.50 (1.00–6.21) 0.049 2.98 (1.23–7.20) 0.015
AR= aortic regurgitation; AS= aortic stenosis; AV= aortic valve; CI= conﬁdence interval; CoA= aortic coarctation;
OR= odds ratio
Table 3. Progression of disease.
n (%) of patients
(n= 227)
Age (mean± SD)
(years)
Moderate or severe AV
dysfunction
122 (44.0) 36± 16
Severe AV dysfunction 66 (29.1) 43± 13
Moderate or severe AS 78 (34.4) 39± 15
Severe AS 53 (19.1) 43± 14
Moderate or severe AR 80 (35.2) 34± 14
Severe AR 13 (5.7) 43± 11
Aortic dilatation (>40mm) 70 (30.8) 42± 15
Aortic dilatation (>45mm) 34 (12.3) 45± 13
AR= aortic regurgitation; AS= aortic stenosis; AV= aortic valve
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of 44± 13 years. Aortic stenosis was the most com-
mon indication for intervention (64% of cases). Only
four patients later required aortic valve re-operation –
those subjected to aortic valve repair, percutaneous
valvulotomy, and one of the aortic homograft
required an aortic valve replacement later on during
the follow-up. The 20-year aortic valve surgery inci-
dence was 35± 4% (Fig 4). In total, 35 patients
(15.4%) underwent a thoracic aorta intervention –
60% of cases for aortic dilatation, 37% for aortic
coarctation, and only one case for aortic dissection.
The indications for surgical intervention for aortic
dilatation were aortic diameter ⩾ 45mm and need for
a concomitant aortic valve surgery (71.4% of cases);
aortic diameter ⩾ 50mm and presence of other risk
factors for aortic dissection (9.5%); and aortic dia-
meter ⩾ 55mm in the remaining four patients
(19%). There was only one patient who required
aortic re-operation, submitted initially for isolated
ascending aortic graft and later required a Bentall
procedure. The 20-year incidence of surgery for aortic
dilatation was 13± 3%. A total of 13 patients
required surgery for aortic coarctation, with four cases
of re-coarctation, leading to a 20-year rate of 6± 2%
(Fig 5). The peak invasive transcoarctation of the
aorta gradient was 60± 35mmHg at the time of the
intervention.
Cardiac events according to presence or absence
of baseline moderate–severe aortic valve dysfunction
are presented in Fig 6. The incidence rate of the
composite end point and of interventional events
at 20 years of follow-up in patients with no
baseline aortic valve dysfunction was 33±5 and
26± 5%, respectively, which was signiﬁcantly
lower (p< 0.001) compared with the rates of events
in those with baseline moderate–severe aortic valve
dysfunction.
Predictors of primary outcomes
The candidate variables examined by univariate ana-
lysis are shown in Tables 6 and 7. None of the vari-
ables were highly correlated with each other (r<0.7).
On multivariate analysis, the independent predictors
of the composite end point were baseline moderate or
severe aortic valve dysfunction (hazard ratio, 3.19;
95% conﬁdence interval 1.35–7.54; p< 0.01) and
aortic valve leaﬂets calciﬁcation (hazard ratio, 4.72;
conﬁdence interval, 1.91–11.64; p< 0.005). The
independent predictors of interventional events –
thoracic aorta and aortic valve interventions – were
age above 30 years (hazard ratio, 2.59; conﬁdence
interval, 1.12–5.99; p< 0.05), hypertension (hazard
ratio, 2.49; conﬁdence interval, 1.07–5.80;
p< 0.05), hyperlipidaemia (hazard ratio, 3.46; con-
ﬁdence interval, 1.15–10.43; p< 0.05), moderate or
severe aortic stenosis (hazard ratio, 7.65; conﬁdence
Figure 1.
Survival during the follow-up of adults with bicuspid aortic valve.
Survival (± SD) at 10 years, 20 years, and end of follow-up
are indicated.
Figure 2.
Incidence of medical (death, aortic dissection, native aortic valve
endocarditis, congestive heart failure, arrhythmias, ischaemic heart
disease requiring hospital admission; blue dotted line),
interventional (aortic valve, thoracic aorta; green solid line), and
total events (medical events or interventional events; red dotted and
dashed line). The event rates (± SD) at 10, 20 years, and end of
follow-up are indicated.
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interval, 2.97–19.73; p< 0.001), and moderate
or severe aortic regurgitation (hazard ratio, 4.17;
conﬁdence interval, 1.63–10.43; p< 0.005).
Discussion
In this study of 227 patients with bicuspid aortic
valve followed-up in a tertiary hospital centre, with a
mean age of 28± 14 years and a male:female ratio of
~2 : 1, 29.1% developed severe aortic valve dysfunc-
tion and 12.3% attained thoracic aorta diameters
above 45mm; 39% of patients had at least one
primary cardiac event during a mean follow-up of 13
years. The most frequent events were aortic valve
surgery for aortic stenosis (17.2% of patients),
ascending thoracic aorta surgery for aortic dilatation
(9.7% of patients), and aortic valve surgery for aortic
regurgitation (7.5% of patients). The fact that aortic
stenosis requiring surgery was the principal morbid
event is concordant with previous population-based
and tertiary-referral-based studies.5,13,14 We highlight
not only its frequency, with a 20-year incidence of
24±4%, but also the younger age at its occurrence,
at a mean age of 45± 13 years, lower than the average
5–10 years earlier than that expected for tricuspid aortic
stenosis described in the literature.15
Only a few published articles have estimated rates
of progressive aortic dilatation in adults with bicus-
pid aortic valves with a long follow-up period.
Thanassoulis et al16 estimated the annual rate of
aortic enlargement in 156 bicuspid aortic valve
patients followed-up for 3.8 years, and 68 patients
were evaluated during nearly 4 years by Ferencik
et al.17 Our study included 227 patients, with a mean
duration of aorta dimensions follow-up of 9 years,
both higher than those in previously described stu-
dies. Dilatation progressed at faster rates in the
proximal ascending aorta, which is consistent with
that described in those studies. We also found that
the presence of aortic valve dysfunction, especially
baseline moderate-to-severe aortic regurgitation, has
a repercussion in rate of aortic dilatation, which is
Table 5. Cardiac outcomes.
Total of
patients
(n = 227)
Age
(mean± SD)
(years)
Baseline AV
dysfunction
(n= 74)
No baseline AV
dysfunction
(n= 153) p
Composite end point [n (%)] 88 (38.8) 41± 14 48 (64.9) 40 (26.1) <0.001
Medical* [n (%)] 38 (16.7) 43± 15 22 (29.7) 16 (10.5) <0.001
Death 7 (3.1) 41± 14 4 (5.4) 3 (2) 0.219
Cardiac death 2 (0.9) 44± 16 2 (2.7) 0 (0) 0.105
Aortic valve endocarditis 11 (4.8) 34± 10 7 (9.5) 4 (2.6) <0.05
Aortic dissection 2 (0.9) 40± 13 2 (2.7) 0 (0) 0.105
Hospital admission for heart failure 7 (3.1) 48± 20 4 (5.4) 3 (2) 0.219
Hospital admission for stroke 6 (2.6) 41± 17 4 (5.4) 2 (1.3) 0.090
Hospital admission for arrhythmias 12 (5.3) 50± 14 4 (5.4) 8 (5.2) 1.000
Hospital admission for CAD 6 (2.6) 48± 13 4 (5.4) 2 (1.3) 0.090
Interventional* [n (%)] 74 (32.6) 42± 14 43 (58.1) 31 (20.3) <0.001
Intervention on aortic valve 61 (26.9) 44± 13 42 (56.8) 20 (13.1) <0.001
AV intervention for AS 39 (17.2) 45± 13 28 (37.8) 12 (7.8) <0.001
AV intervention for AR 17 (7.5) 45± 13 10 (13.5) 7 (4.6) <0.05
AV intervention for endocarditis 6 (2.6) 41± 12 5 (6.8) 1 (0.7) <0.05
Intervention on thoracic aorta 35 (15.4) 42± 16 17 (23) 18 (11.8) <0.05
TA intervention for aortic dilatation 22 (9.7) 47± 13 14 (18.9) 8 (5.2) <0.005
TA intervention for CoA 13 (5.7) 34± 19 2 (2.7) 11 (7.2) 0.231
TA intervention for aortic dissection 1 (0.4) 31 1 (1.4) 0 (0) 0.326
Type of intervention
Mechanical aortic valve replacement 35 (15.4)
Bioprosthetic aortic valve replacement 6 (2.6)
Aortic homograft 2 (0.9)
Aortic valve repair 2 (0.9)
Percutaneous aortic valvulotomy 1 (0.4)
Ascending aortic graft and AV replacement 19 (8.4)
Ascending aortic graft 4 (1.8)
Percutaneous angioplasty for CoA 6 (2.6)
Prosthetic patch aortoplasty for CoA 5 (2.2)
Resection of CoA and end-to-end anastomosis 3 (1.3)
AR= aortic regurgitation; AS= aortic stenosis; AV= aortic valve; CAD= coronary artery disease; CoA= aortic coarctation; pts= patients;
TA= thoracic aorta
*Categories are not mutually exclusive
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consistent with previously published studies.16,18
The increased stroke volume imposed by aortic
regurgitation enhances proximal ascending aorta wall
stress, which can ultimately lead to faster aorta
expansion and explain this result.
It is not surprising that baseline aortic valve dys-
function had independently predicted the occurrence
of a primary cardiac event, a fact that is consistent
with the results of the most recent major studies
that addressed this issue.13,14 In these patients,
the incidence rate of the composite end point at
20 years of follow-up was as high as 75± 7%, which
is clearly representative of the signiﬁcant morbidity
associated with bicuspid aortic valve. It should
also be noted that even those patients without
baseline aortic valve dysfunction are at risk of having
events, with a 20-year incidence of 33± 5 and
26± 5% of total events and interventional events,
respectively.
Aortic valve leaﬂet calciﬁcation was also an inde-
pendent predictor of the occurrence of a cardiac event.
Turbulent ﬂow through a bicuspid aortic valve,
which has an altered architecture, plays a role in
premature valve degeneration and calciﬁcation,19
which ultimately progresses to aortic valve dysfunc-
tion. Thus, patients with valve degeneration, even if
they had a normally functioning bicuspid valve, need
Figure 3.
Incidence of total interventional events (aortic valve, thoracic aorta;
green solid line), aortic valve intervention (blue dotted line), and
thoracic aorta intervention (pink dashed and dotted line). The
event rates (± SD) at 10 years, 20 years, and the end of follow-up
are indicated.
Figure 4.
Incidence of total aortic valve intervention (for aortic stenosis, aortic
regurgitation, endocarditis; blue dotted line), aortic valve
intervention for aortic stenosis (blue solid line), for aortic
regurgitation (grey dashed line), and for endocarditis (purple
dashed and dotted line). The event rates (± SD) at 10, 20 years,
and the end of follow-up are indicated.
Figure 5.
Incidence of total thoracic aorta intervention (for aortic dilatation,
aortic dissection, aortic coarctation; pink dashed and dotted line),
thoracic aorta intervention for aortic dilatation (pink dashed line),
for aortic coarctation (purple dashed line), and for aortic dissection
(purple solid line). The event rates (± SD) at 10, 20 years, and
the end of follow-up are indicated.
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closest follow-up than those without it13; however,
other mechanisms rather than turbulent ﬂow could be
involved in development of bicuspid aortic valve
degeneration. As previously described for tricuspid
aortic valves, some cardiovascular risk factors showed
signiﬁcant association with progression of disease.20–22
This probably applies to bicuspid valves as well, and
could be a possible explanation for our ﬁndings of
hyperlipidaemia and hypertension as independent
predictors of interventional events.
Figure 6.
Incidence of events during follow-up according to the presence (green solid line) or absence (blue dashed line) of moderate or severe aortic valve
dysfunction at baseline (including moderate or severe aortic stenosis or regurgitation). (a) Incidence of total events (medical and interventional).
(b) Incidence of interventional events (aortic valve, thoracic aorta). (c) Incidence of medical events (death, aortic dissection, native aortic valve
endocarditis, congestive heart failure, arrhythmias, and ischaemic heart disease requiring hospital admission). The event rates (± SD) at 10,
20 years, and the end of follow-up are indicated.
Table 6. Predictors of total events.
Univariate analysis Multivariate analysis
Candidate variables HR (95% CI) p value HR (95% CI) p value
Baseline age >30 years 8.59 (4.55–16.24) <0.001 1.22 (0.38–3.94) 0.742
Male sex 0.77 (0.43–1.37) 0.367
Hypertension 4.43 (2.36–8.31) <0.001 1.88 (0.77–4.58) 0.165
Hyperlipidaemia 8.68 (3.38–22.25) <0.001 1.56 (0.50–4.85) 0.444
Diabetes mellitus 2.37 (0.39–14.47) 0.351
Smoking status 2.58 (1.22–5.43) <0.05 2.29 (0.81–6.46) 0.118
Obesity 0.82 (0.26–2.56) 0.733
Previous diagnosis of CoA 1.32 (0.67–2.58) 0.419
Previous aorta/AV intervention 0.69 (0.35–1.36) 0.281
TAA dilatation (>40mm) 6.14 (2.61–14.43) <0.001 1.31 (0.37–4.62) 0.655
Moderate–severe AV dysfunction 5.22 (2.87–9.49) <0.001 3.19 (1.35–7.54) <0.01
Moderate–severe AS 2.99 (1.37–6.53) <0.01 3.08 (0.78–12.12) 0.108
Moderate–severe AR 2.08 (0.93–4.62) 0.073
Leaﬂet thickening 4.63 (2.49–8.60) <0.001 1.96 (0.63–6.07) 0.244
Leaﬂet calciﬁcation 17.18 (6.32–46.72) <0.001 4.72 (1.91–11.64) <0.005
LVH 4.16 (1.95–8.88) <0.001 2.20 (0.84–5.76) 0.108
LVD 3.07 (1.50–6.29) <0.005
LVEF <50% 3.26 (0.59–18.20) 0.178
LAE 4.37 (1.61–11.87) <0.005 2.18 (0.55–8.65) 0.269
RVD 1.46 (0.09–23.89) 0.791
AR= aortic regurgitation; AS= aortic stenosis; AV= aortic valve; CI= conﬁdence interval; CoA= aortic coarctation;
HR= hazard ratio; LAE= left atrial enlargement; TA= thoracic ascending aorta; LVD= left ventricular dilatation;
LVEF= left ventricular ejection fraction; LVH= left ventricular hypertrophy; RVD= right ventricular dilatation
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Incidence of medical events was almost half of
interventional events, with a 20-year incidence of
20± 4%. In total, 11 patients (5%) had at least an
episode of infectious endocarditis during the follow-
up, slightly higher than the 2–3% reported in pre-
vious population-based and tertiary-referral-based
studies.13,14,23 Surgical treatment, however, was
required in only 54% of these patients, which is
similar to rates described for general population
endocarditis24 and far below the 75% reported in a
recent multi-centre observational study.25 Another
encouraging observation was the low rate of dissec-
tion, with only two cases in the 227 patients analysed
(0.07%/patient-year), similar to that observed by
Tzemos et al (0.1%/patient-year)14 and Michela et al
(0.03%/patient-year).26 The overall relatively lower
dissection incidence in bicuspid aortic valve could be
partially explained by prophylactic aortic repair, the
larger diameters at which dissection occurs compared
with tricuspid aortic valve patients with ascending
aortic dissection,9 and also by the higher proportion
of bicuspid aortic valve patients with no progression
of aortic dilatation compared with the aortic root in
Marfan syndrome patients.27
Study limitations
First, our study has limitations related to the enrol-
ment of cases from a single tertiary centre. This could
have led to overestimation of the severity of valvular
lesions, aortic dimensions, and rates of progression as
our patients might have had more advanced BAV
than those in community-based studies. Another fact
that may contribute to this overestimation is our
cohort including ~30% patients with associated
CHD and 50% patients previously followed-up by
paediatric cardiologists. This probably represents a
higher morbidity population than adults in com-
munity receiving a new diagnosis of bicuspid aortic
valve. Therefore, the morbidity associated with
bicuspid aortic valve could be overestimated as
compared with that in the general population.
Second, we would like to highlight the fact that
the studied population included mostly young adults
and were relatively free of baseline aortic dilatation.
This may have led to a predilection for valve events in
follow-up, as age and diameter of the aorta are two of
the main predictors of aorta events
Third, we also acknowledge the inability to eval-
uate other important contributing factors for out-
comes as data were retrospectively collected.
To conclude, with major improvements in echo-
cardiography during the study period, with higher
reliable measurements of the severity of aortic valve
disease since the emergency of continuous-wave
Doppler, we consider that adequate techniques were
used throughout the study period to rank the severity
of aortic valve function, always following the state of
Table 7. Predictors of Interventional events.
Univariate analysis Multivariate analysis
Candidate variables HR (95% CI) p value HR (95% CI) p value
Baseline age >30 years 8.03 (4.27–15.09) <0.001 2.59 (1.12–5.99) <0.05
Male sex 0.68 (0.37–1.23) 0.198
Hypertension 4.02 (2.15–7.52) <0.001 2.49 (1.07–5.80) <0.05
Hyperlipidaemia 6.57 (2.84–15.20) <0.001 3.46 (1.15–10.43) <0.05
Diabetes Mellitus 3.09 (0.50–18.89) 0.223
Smoking status 2.66 (1.26–5.59) <0.05 2.52 (0.96–6.60) 0.059
Obesity 0.77 (0.23–2.57) 0.672
Previous diagnosis of CoA 1.29 (0.64–2.57) 0.474
Previous aorta/AV intervention 1.76 (0.84–3.70) 0.134
TAA dilatation (>40mm) 5.12 (2.31–11.32) <0.001 1.91 (0.61–5.96) 0.267
Moderate–severe AV dysfunction 5.46 (2.97–10.02) <0.001 1.85 (0.59–5.83) 0.295
Moderate–severe AS 7.57 (3.57–16.06) <0.001 7.65 (2.97–19.73) <0.001
Moderate–severe AR 2.49 (1.26–4.93) <0.01 4.17 (1.63–10.43) <0.005
Leaﬂet thickening 3.86 (2.02–7.41) <0.001 1.63 (0.70–3.81) 0.257
Leaﬂet calciﬁcation 8.01 (3.63–17.68) <0.001 1.59 (0.48–5.26) 0.446
LVH 3.86 (1.85–8.08) <0.001 1.02 (0.34–3.05) 0.970
LVD 2.94 (1.44–6.00) <0.005 1.88 (0.61–5.80) 0.275
LVEF <50% 4.31 (0.77–24.11) 0.096
LAE 2.34 (0.93–5.92) 0.071
RVD 2.00 (0.12–32.79) 0.627
AR= aortic regurgitation; AS= aortic stenosis; AV= aortic valve; CI= conﬁdence interval; CoA= aortic coarctation; HR= hazard ratio; LAE= left
atrial enlargement; TA= thoracic ascending aorta; LVD= left ventricular dilatation; LVEF= left ventricular ejection fraction; LVH= left ventricular
hypertrophy; RVD= right ventricular dilatation
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art. We are also aware that the transthoracic echo-
cardiography measurements of the thoracic aorta are
substantially lower than those measured by more
accurate methods such as gate CT28 or MRI, and as
we did not compare the diameters between these
methods in patients analysed by the two techniques
we cannot ensure that the rate of thoracic aorta dila-
tation is underestimated in our study.
Conclusions
In this tertiary referral centre study of adults with
bicuspid aortic valve, the long-term survival was
excellent but with occurrence of frequent cardiovas-
cular events, mainly aortic valve or thoracic aorta
interventions. Patients with aortic valve dysfunction
and leaﬂets calciﬁcation at baseline were at higher
risk for cardiac events. Not only age and moderate or
severe aortic valve stenosis and regurgitation were
independent predictors of interventional events but
also were cardiovascular risk factors such as hyper-
tension and hyperlipidaemia. Even those with no
baseline aortic valve dysfunction had a high 20-year
incidence rate of interventional events. Therefore, all
patients with bicuspid aortic valve will need serial
evaluations of aortic dimensions and aortic valve,
with a periodicity dictated by the clinical condition
and individual risk factors.
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